Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advance in Vaccine Development"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2282
Special Issue Editor
Interests: vaccination strategy; antibody response; antiviral immunity; mechanism of vaccination
Special Issue Information
The historically rapid development and deployment of COVID-19 vaccines exemplify the progress that has been achieved in both basic research and the manufacturing technology of vaccines during the past few decades, while a sobering fact is that effective vaccines against tough “bugs”, such as HIV and TB, are still lacking. In the meantime, vaccines against cancer, Alzheimer’s and allergic diseases are also earnestly pursued. To tackle these challenges, continuous efforts are required to explore new approaches and technologies for vaccine development.
Given that the immunogenicity and efficacy of vaccines are determined by both vaccine formulation and host factors, the aim of this Special Issue is to address scientific questions related to these aspects. All research articles, reviews, methodologies able to shed new light on improving antigen design, developing better adjuvants and more efficient delivery techniques, optimizing vaccination strategies and understanding host factors related to vaccine efficacy are welcome. Studies/reviews focused on mucosal vaccine development are also included.
We look forward to receiving your contributions.
Prof. Dr. Yanmin Wan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antigen design
- vaccination strategy
- vaccine effect
- mucosal immunity
- recombinant vector vaccine
- delivery technique